Albany Molecular Research Overview
Albany Molecular Research (AMRI) has a P/E ratio of -13.18, below the sector sector average of 34.56.
Get informed when a big investor buys or sells
+ Follow-13.18
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for AMRI is -13.18. That is below the sector sector average of 34.56. Investors often review this figure alongside Albany Molecular Research's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, AMRI currently prints -13.18 for P/E ratio, while the sector average sits near 34.56. That is roughly 138.1% below the sector mean. Large gaps often invite a closer look at Albany Molecular Research's growth, margins, and balance sheet.
A P/E ratio of -13.18 for Albany Molecular Research is not 'good' or 'bad' on its own. Compare it with the peer average (34.56) and with AMRI's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting AMRI's P/E ratio (-13.18), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
